- Previous Close
777.35 - Open
788.90 - Bid 775.65 x --
- Ask 780.05 x --
- Day's Range
761.75 - 798.00 - 52 Week Range
670.05 - 1,998.00 - Volume
6,924 - Avg. Volume
12,587 - Market Cap (intraday)
39.323B - Beta (5Y Monthly) 1.96
- PE Ratio (TTM)
35.21 - EPS (TTM)
22.02 - Earnings Date May 21, 2025 - May 26, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 13, 2012
- 1y Target Est
1,502.67
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins, veterinary products, and non-antibiotics. The company has multi-therapeutic presence in anti-infectives, anti-inflammatory, central nervous system, cardiovascular segment, nutraceuticals, and other oral and sterile products, as well as offers new drug discovery systems and pharmaceutical research and development services. It also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is based in Narsinghpur, India. Orchid Pharma Limited operates as a subsidiary of Dhanuka Laboratories Limited.
www.orchidpharma.com871
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: ORCHPHARMA.BO
View MorePerformance Overview: ORCHPHARMA.BO
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ORCHPHARMA.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ORCHPHARMA.BO
View MoreValuation Measures
Market Cap
39.32B
Enterprise Value
38.49B
Trailing P/E
35.26
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.36
Price/Book (mrq)
3.21
Enterprise Value/Revenue
4.27
Enterprise Value/EBITDA
24.74
Financial Highlights
Profitability and Income Statement
Profit Margin
12.30%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
9.02B
Net Income Avi to Common (ttm)
1.11B
Diluted EPS (ttm)
22.02
Balance Sheet and Cash Flow
Total Cash (mrq)
2.44B
Total Debt/Equity (mrq)
13.47%
Levered Free Cash Flow (ttm)
--